Other Events ·
RxSight, Inc. entered into a License, Collaboration and Development Agreement with Alcon Pharmaceuticals, Ltd to…
RXSTRxSight, Inc.
RxSight, Inc. entered into a License, Collaboration and Development Agreement with Alcon Pharmaceuticals, Ltd to develop and commercialize light-adjustable versions of certain Alcon simultaneous vision intraocular lenses. The agreement includes a $60 million upfront cash payment to RxSight, with potential milestone payments of $70 million for feasibility, $30 million for FDA submission, and $40 million for regulatory approval, plus 30% royalties on net sales. RxSight, Inc. is a medical technology company that develops and commercializes light-adjustable intraocular lenses for ophthalmic surgery.